Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$163.52 - $218.66
Previous CloseN/A
Volume1.02M
Average Volume (3M)6.16M
Market Cap
$337.52B
Enterprise Value$340.28B
Total Cash (Recent Filing)$5.18B
Total Debt (Recent Filing)$69.89B
Price to Earnings (P/E)81.5
Beta0.33
Next Earnings
Jul 25, 2025EPS Estimate
3.22Last Dividend Ex-Date
Apr 15, 2025Dividend Yield3.43%
Share Statistics
EPS (TTM)2.46
Shares Outstanding1,766,403,100
10 Day Avg. Volume4,558,435
30 Day Avg. Volume6,162,605
Financial Highlights & Ratios
PEG Ratio9.22
Price to Book (P/B)16.59
Price to Sales (P/S)0.00
P/FCF Ratio11.80
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit7.66
Enterprise Value/Ebitda4.11
Forecast
1Y Price Target
$212.80Price Target Upside11.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
AbbVie News
Bulls Say, Bears Say
Bulls Say
FDA ApprovalEmrelis (Teliso-V) granted accelerated approval by the FDA for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.
Obesity Market PotentialThe company sees significant upside in obesity due to the market size and low penetration rates, with potential backbone therapy through amylin.
Pipeline DevelopmentABBV's underappreciated mid-stage pipeline is expected to be ready for prime-time in the near future.
Bears Say
Pipeline OpportunitiesThe late-stage pipeline comprises mostly label expansions that offer less opportunity than those already approved.
Pipeline RiskA comparatively lighter late-stage pipeline and in therapeutic areas that may not scale to the current I&I franchise add risk to AbbVie's relative safety positioning.
Policy RiskA higher perceived policy risk than peers from PBM reform/MFN discounting adds risk to AbbVie's relative safety positioning.
Ownership Overview
0.07% Insiders
21.49% Mutual Funds
14.10% Other Institutional Investors
41.98% Public Companies and Individual Investors
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $163.52 and its highest was $218.66 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $337.52B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jul 25, 2025 which is in 38 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Apr 25, 2025. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.379 by $0.081.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.639 which represents an annual dividend yield of 3.43%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.22.
How many shares outstanding does AbbVie have?
AbbVie has 1,766,403,100 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.46 in its last earnings report, beating expectations of $2.379. Following the earnings report the stock price went up 3.155%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
AbbVie Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$212.80 (11.50% Upside)
$212.80 (11.50% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 93%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 753.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.88%
12-Months-Change
Fundamentals
Return on Equity
88.15%
Trailing 12-Months
Asset Growth
-8.54%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance in the Ex-Humira platform and increased guidance, driven by growth in immunology and neuroscience. However, there were significant challenges in Humira and aesthetics sales, with competitive pressures impacting Imbruvica. Overall, the company shows strong momentum despite these challenges.Read More>ABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$212.80
▲(11.50%Upside)